Indication
VAIN III
1 clinical trial
2 products
Clinical trial
A Multicenter,Randomized, Placebo-Controlled, and Double-blind Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity and Safety of Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Aged 18-45 YearsStatus: Terminated, Estimated PCD: 2023-03-23
Product
Placebo